Our precision therapy programs use genomics to understand how an individual’s genes affect their response to medication and targeted treatments.
GenoRx Program: Through pharmacogenomics (PGx), we use genomics to understand how an individual’s genes affect their response to medication. These gene variations can be found through PGx testing so providers can improve medication efficacy and minimize adverse drug reactions. Learn more.
GenACT Program: If a patient develops cancer, our GenACT precision oncology program provides Comprehensive Genomic Profiling (CGP) tests to diagnose genetic anomalies in the tumor for targeted therapy. This information helps us guide actionable and personalized treatment plans—both approved and investigational, including clinical trial recommendations.Learn more.
The Providence Molecular Tumor Board (PMTB) is a systemwide resource to help caregivers with challenging molecular oncology cases. Caregivers use advanced technology to "virtually" bring their cases to experts in oncology, anatomic and molecular pathology, genomics, cancer genetics, pharmacology, and clinical research across Providence, who address clinical questions and discuss the therapeutic relevance of variants identified in a patient's tumor, clinical trial considerations, and issues related to the diagnostic and prognostic significance of molecular findings. To help caregivers streamline their case preparation, the PMTB uses a highly advanced software tool called the GenACT Dashboard.
"When faced with rare tumors and complex decision-making, Providence Genomics has been a valuable resource to help me provide personalized and cutting-edge care to my patients."
.jpeg)
Stay up to date on our research by following some of our primary researchers:
